Resistance patterns to anti-PD-1 therapy in metastatic melanoma

被引：3
|
作者：
Ozgun, Alpaslan
Sondak, Vernon K.
Markowitz, Joseph
机构：
[1] Univ S Florida, Morsani Coll Med, Moffitt Canc Ctr, Dept Cutaneous Oncol, Tampa, FL USA
[2] Univ S Florida, Morsani Coll Med, Dept Oncol Sci, Dept Cutaneous Oncol, Tampa, FL USA
来源：
CHINESE CLINICAL ONCOLOGY | 2016年 / 5卷 / 06期
关键词：
D O I：
10.21037/cco.2016.08.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma
    Ladwa, Rahul
    Atkinson, Victoria
    MELANOMA RESEARCH, 2017, 27 (02) : 168 - 170
  • [22] Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
    Ascierto, Maria L.
    Makohon-Moore, Alvin
    Lipson, Evan J.
    Taube, Janis M.
    McMiller, Tracee L.
    Berger, Alan E.
    Fan, Jinshui
    Kaunitz, Genevieve J.
    Cottrell, Tricia R.
    Kohutek, Zachary A.
    Favorov, Alexander
    Makarov, Vladimir
    Riaz, Nadeem
    Chan, Timothy A.
    Cope, Leslie
    Hruban, Ralph H.
    Pardoll, Drew M.
    Taylor, Barry S.
    Solit, David B.
    Iacobuzio-Donahue, Christine A.
    Topalian, Suzanne L.
    CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3168 - 3180
  • [23] LESION-SPECIFIC PATTERNS OF RESPONSE AND PROGRESSION WITH ANTI-PD-1 TREATMENT IN METASTATIC MELANOMA (MM)
    Lyle, M.
    Lee, J.
    Menzies, A. M.
    Chan, M. M. K.
    Clements, A.
    Carlino, M. S.
    Kefford, R.
    Long, G. V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 63 - 63
  • [24] Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).
    Lyle, Megan Kate
    Lee, Jenny H. J.
    Menzies, Alexander M.
    Chan, Matthew M. K.
    Clements, Arthur
    Carlino, Matteo S.
    Kefford, Richard
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] The efficacy and safety of anti-PD-1 therapy in metastatic sarcomas
    Yang, Jilong
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
    Brunot, Angelique
    Jeudy, Geraldine
    Tas, Mathieu
    Guillot, Bernard
    Kramkimel, Nora
    Mortier, Laurent
    Mansard, Sandrine
    Lebbe, Celeste
    Blom, Astrid
    Le Corre, Yannick
    Montaudie, Henri
    Prey, Sorilla
    Campillo-Gimenez, Boris
    Lesimple, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma
    Kubo, Yosuke
    Fukushima, Satoshi
    Inamori, Yukiko
    Tsuruta, Mina
    Egashira, Sho
    Yamada-Kanazawa, Saori
    Nakahara, Satoshi
    Tokuzumi, Aki
    Miyashita, Azusa
    Aoi, Jun
    Kajihara, Ikko
    Tomita, Yusuke
    Wakamatsu, Kazumasa
    Jinnin, Masatoshi
    Ihn, Hironobu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 93 (01) : 33 - 40
  • [28] Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma
    Amini-Adle, M.
    Balme, B.
    Dalle, S.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (12): : 802 - 803
  • [29] Correlating skin toxicity and steroid treatment with outcomes of anti-PD-1 therapy for patients with metastatic melanoma
    Quach, Henry T.
    Johnson, Douglas B.
    Dewan, Anna K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB39 - AB39
  • [30] Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy
    Acar, Caner
    Yuksel, Haydar cagatay
    Sahin, Gokhan
    Acar, Fatma Pinar
    Gunenc, Damla
    Karaca, Burcak
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
12345